ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
A cost-effectiveness analysis of escitalopram as first line treatment of depression in Sweden
Primary Care Psychiatry
◽
10.1185/135525705x20375
◽
2004
◽
Vol 9
(4)
◽
pp. 153-162
◽
Cited By ~ 7
Author(s):
Mickael Löthgren
◽
Michiel Hemels
◽
Clément François
◽
Bengt Jönsson
Keyword(s):
Cost Effectiveness
◽
Cost Effectiveness Analysis
◽
Line Treatment
◽
First Line
◽
Effectiveness Analysis
◽
Treatment Of Depression
◽
First Line Treatment
Download Full-text
Related Documents
Cited By
References
Cost-Effectiveness Analysis Of Panitumumab + Folfox Compared To Cetuximab + Folfiri As First-Line Treatment For Patients With Wild-Type (Wt) Ras (Exons 2, 3, And 4 Of Kras And Nras) Metastatic Colorectal Cancer (Mcrc) In Colombia
Value in Health
◽
10.1016/j.jval.2015.09.1188
◽
2015
◽
Vol 18
(7)
◽
pp. A460
◽
Cited By ~ 2
Author(s):
J Vargas-Valencia
◽
J Garcia Perlaza
Keyword(s):
Colorectal Cancer
◽
Cost Effectiveness
◽
Metastatic Colorectal Cancer
◽
Cost Effectiveness Analysis
◽
Line Treatment
◽
Wild Type
◽
First Line
◽
Effectiveness Analysis
◽
First Line Treatment
Download Full-text
Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
Journal of Medical Economics
◽
10.1080/13696998.2017.1285780
◽
2017
◽
Vol 20
(6)
◽
pp. 574-584
◽
Cited By ~ 3
Author(s):
Fernando Rivera
◽
Manuel Valladares
◽
Salvador Gea
◽
Noemí López-Martínez
Keyword(s):
Colorectal Cancer
◽
Cost Effectiveness
◽
Metastatic Colorectal Cancer
◽
Cost Effectiveness Analysis
◽
Line Treatment
◽
Wild Type
◽
First Line
◽
Effectiveness Analysis
◽
First Line Treatment
Download Full-text
Cost-Effectiveness Analysis Comparing FOLFIRINOX and Nab-Paclitaxel (Abaraxane) Plus Gemcitabine For First-Line Treatment Of Patients with Metastatic Pancreatic Cancer from the US Societal Perspective
Value in Health
◽
10.1016/j.jval.2016.03.1607
◽
2016
◽
Vol 19
(3)
◽
pp. A153
Author(s):
W Cheng
◽
JW Hay
Keyword(s):
Pancreatic Cancer
◽
Cost Effectiveness
◽
Societal Perspective
◽
Cost Effectiveness Analysis
◽
Metastatic Pancreatic Cancer
◽
Line Treatment
◽
First Line
◽
Effectiveness Analysis
◽
The Us
◽
First Line Treatment
Download Full-text
Commentary on: A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder
International Urogynecology Journal
◽
10.1007/s00192-018-3662-y
◽
2018
◽
Vol 29
(8)
◽
pp. 1221-1221
Author(s):
Abdelmageed Abdelrahman
Keyword(s):
Cost Effectiveness
◽
Overactive Bladder
◽
Cost Effectiveness Analysis
◽
Line Treatment
◽
First Line
◽
Effectiveness Analysis
◽
Onabotulinumtoxin A
◽
First Line Treatment
Download Full-text
Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong
Cost Effectiveness and Resource Allocation
◽
10.1186/s12962-020-0200-9
◽
2020
◽
Vol 18
(1)
◽
Cited By ~ 1
Author(s):
Herbert H. Loong
◽
Carlos K. H. Wong
◽
Linda K. S. Leung
◽
S. C. Tan
◽
Jason Jen
◽
...
Keyword(s):
Hong Kong
◽
Cost Effectiveness
◽
Standard Of Care
◽
Cost Effectiveness Analysis
◽
Advanced Melanoma
◽
Line Treatment
◽
First Line
◽
Effectiveness Analysis
◽
First Line Treatment
Download Full-text
Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma
Oral Oncology
◽
10.1016/j.oraloncology.2019.04.022
◽
2019
◽
Vol 94
◽
pp. 80-85
◽
Cited By ~ 6
Author(s):
Xudong Chen
◽
Weiting Liang
◽
Ning Wan
◽
Li Zhang
◽
Yunpeng Yang
◽
...
Keyword(s):
Cost Effectiveness
◽
Nasopharyngeal Carcinoma
◽
Cost Effectiveness Analysis
◽
Line Treatment
◽
First Line
◽
Effectiveness Analysis
◽
Metastatic Nasopharyngeal Carcinoma
◽
First Line Treatment
Download Full-text
A Cost-Effectiveness Analysis of Gefitinib as the First Line Treatment in Patients With Positive Egfr Mutation In Metastatic or Locally Advanced non-Small Cell
Value in Health
◽
10.1016/j.jval.2015.09.1110
◽
2015
◽
Vol 18
(7)
◽
pp. A446
◽
Cited By ~ 1
Author(s):
T Piha
◽
D Barbosa
◽
L Fahham
Keyword(s):
Cost Effectiveness
◽
Egfr Mutation
◽
Locally Advanced
◽
Cost Effectiveness Analysis
◽
Small Cell
◽
Line Treatment
◽
First Line
◽
Effectiveness Analysis
◽
First Line Treatment
Download Full-text
Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma: A lifetime cost-effectiveness analysis
Cancer
◽
10.1002/(sici)1097-0142(19961201)78:11<2366::aid-cncr15>3.0.co;2-z
◽
1996
◽
Vol 78
(11)
◽
pp. 2366-2373
◽
Cited By ~ 21
Author(s):
Andrea Messori
◽
Sabrina Trippoli
◽
Paola Becagli
◽
Enrico Tendi
Keyword(s):
Cost Effectiveness
◽
Ovarian Carcinoma
◽
Lifetime Cost
◽
Cost Effectiveness Analysis
◽
Line Treatment
◽
First Line
◽
Advanced Ovarian Carcinoma
◽
Effectiveness Analysis
◽
First Line Treatment
Download Full-text
Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR -Mutated Advanced Non–Small Cell Lung Cancers
Journal of Thoracic Oncology
◽
10.1016/j.jtho.2017.07.013
◽
2017
◽
Vol 12
(10)
◽
pp. 1496-1502
◽
Cited By ~ 18
Author(s):
Christos Chouaid
◽
Laura Luciani
◽
Katell LeLay
◽
Pascal Do
◽
Jaafar Bennouna
◽
...
Keyword(s):
Cost Effectiveness
◽
Cost Effectiveness Analysis
◽
Small Cell
◽
Line Treatment
◽
Small Cell Lung
◽
First Line
◽
Lung Cancers
◽
Effectiveness Analysis
◽
Egfr Mutated
◽
First Line Treatment
Download Full-text
PCN20 Comparison of Nab-paclitaxel PLUS Gemcitabine Versus FOLFIRINOX in First LINE Treatment of Metastatic Pancreatic Cancer in China: A Cost-Effectiveness Analysis
Value in Health Regional Issues
◽
10.1016/j.vhri.2020.07.070
◽
2020
◽
Vol 22
◽
pp. S7-S8
Author(s):
J. Cui
◽
X. Zhang
◽
S. Qu
◽
Y. Liu
◽
C. Ye
◽
...
Keyword(s):
Pancreatic Cancer
◽
Cost Effectiveness
◽
Cost Effectiveness Analysis
◽
Metastatic Pancreatic Cancer
◽
Line Treatment
◽
First Line
◽
Effectiveness Analysis
◽
First Line Treatment
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close